PetIQ Acquires MYOS Corp for Muscle Health Portfolio Expansion

PetIQ, a prominent player in the pet health and wellness sector backed by private equity firm Bansk Group, has significantly expanded its product offerings through the acquisition of MYOS Corp. This strategic move integrates MYOS's specialized muscle health and mobility solutions, centered around its proprietary Fortetropin ingredient, into PetIQ's extensive portfolio. The deal aims to capitalize on the growing consumer demand for advanced, science-backed pet care, particularly in areas promoting longevity and active lifestyles for companion animals.

The acquisition grants PetIQ full ownership of the MYOS brand and its patented Fortetropin technology. This unique bioactive compound is designed to modulate myostatin, a natural inhibitor of muscle growth, thereby supporting muscle maintenance, recovery, and mobility in pets experiencing age-related decline, post-surgery recovery, or injury. The efficacy of Fortetropin has been explored through over a dozen clinical studies across various species, including dogs, cats, and horses, underpinning its scientific validation.

Camillo Pane, CEO of PetIQ, highlighted the strategic alignment of the acquisition with evolving pet parent priorities. "Pet parents are increasingly looking for solutions that support their pets’ mobility, recovery, and long-term vitality, not just treatment after a problem arises," Pane stated. "MYOS has spent over a decade working alongside veterinarians to understand the science around muscle health, leading to the development of Fortetropin as a proprietary, differentiated, clinically supported ingredient." He further emphasized that integrating MYOS allows PetIQ to enter the rapidly expanding muscle health category and cater to the heightened interest in preventive pet care and enhanced quality of life.

This transaction marks a notable expansion for PetIQ, moving beyond its established lines of over-the-counter flea and tick treatments, dental care, and general wellness products. The company, which boasts well-known brands such as PetArmor, Capstar, Nextstar, Minties, VetIQ, and Rocco & Roxie, will leverage its robust national retail, e-commerce, manufacturing, and distribution infrastructure to broaden the reach of MYOS products. This integration is expected to introduce these advanced muscle health solutions to a wider audience of pet owners and veterinary professionals.

MYOS Corp's CEO, Joe Mannello, expressed enthusiasm for the partnership, noting the synergistic benefits. "We’re very excited to partner with PetIQ," Mannello commented. "PetIQ’s distribution reach, brand-building expertise, and operating discipline are exactly what MYOS and Fortetropin need to realize their full potential and reach more pet owners globally." The combined entity is poised to accelerate innovation and market penetration in the specialized pet nutrition and health segment, a market segment experiencing consistent growth driven by increased pet humanization and a focus on preventative health measures.

The deal was facilitated with advisory support from Lincoln International and Davis Polk for PetIQ and Bansk Group. MYOS Corp received counsel from Class VI Partners and Davis Graham. While financial terms were not disclosed, the acquisition underscores the strategic importance of specialized, science-backed ingredients in the competitive pet care industry, a sector valued in the tens of billions globally and projected for continued expansion.